Skip to content


PILA PHARMA is developing a novel type of oral anti-diabetic drug by aiming at the human body receptor, TRPV1, whose discovery recently was awarded with the Nobel prize.
This approach has potential to treat both glucose intolerance and obesities in patients with diabetes type 2, with none or small side effects.
Our research is in clinical stage phase 2.
The company´s share is listed om Nasdaq First North Growth Market in Stockholm under the ticker “PILA”.

Back To Top